H. Lee et al., A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4, CANCER RES, 61(11), 2001, pp. 4467-4473
A variety of receptor-mediated signaling pathways are controlled by both po
sitive and negative extracellular regulators. In this study, we demonstrate
that a naturally occurring secreted form of the human ErbB3 receptor, p85-
soluble ErbB3 (sErbB3), is a potent negative regulator of heregulin (HRG)-s
timulated ErbB2, ErbB3, and ErbB4 activation. We show that p85-sErbB3 binds
to HRG with an affinity comparable to that of full-length ErbB3 and compet
itively inhibits high affinity HRG binding to ErbB2/ErbB3 heterodimers on t
he cell surface of breast carcinoma cells with an IC50 of 0.5 nM. p85-sErbB
3 inhibits HRG-induced phosphorylation of ErbB2, ErbB3, and ErbB4 in breast
carcinoma-derived cell lines and can also block HRG-stimulated activation
of mitogen-activated protein kinase, Akt, and association of ErbB3 with the
phosphatidylinositol 3'-kinase p85 regulatory subunit. Cell growth assays
show that exogenous addition of a 100-fold molar excess of p85-sErbB3 inhib
its HRG-stimulated cell growth by as much as 90%. Whereas several potential
mechanisms of p85-sErbB3 inhibition of ErbB receptor activation exist, our
results suggest that at least one means of inhibition is competition for H
RG binding. The IC50 for both p85-sErbB3- and 2C4 (a monoclonal antibody sp
ecific for ErbB2)-mediated inhibition of HRG binding is approximately 0.5 n
M, although the mechanism of inhibition by these two proteins is distinct.
Together these results suggest that p85-sErbB3 is a naturally occurring neg
ative regulator of MG-stimulated signal transduction that may have importan
t therapeutic applications in human malignancies associated with HRG-mediat
ed cell growth such as breast and prostate cancer.